AEterna Zentaris (AEterna Zentaris) Cash Flow from Discontinued Operations : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is AEterna Zentaris Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

AEterna Zentaris's cash flow from discontinued operations for the three months ended in Dec. 2023 was $0.00 Mil. It means AEterna Zentaris received $0.00 Mil from the sale of part of business quarterly. AEterna Zentaris's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

AEterna Zentaris Cash Flow from Discontinued Operations Historical Data

The historical data trend for AEterna Zentaris's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Cash Flow from Discontinued Operations Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow from Discontinued Operations

Get a 7-Day Free Trial

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow from Discontinued Operations	Get a 7-Day Free Trial															-	-	-	-	-

AEterna Zentaris Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

AEterna Zentaris Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (AEterna Zentaris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (NAS:AEZS) » Definitions » Cash Flow from Discontinued Operations

Comparable Companies

Traded in Other Exchanges

ET8:Germany ET8:Germany AEZS:Canada

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.